CHARLOTTE, N.C., June 22, 2010 -- Chelsea Therapeutics International, Ltd. (Nasdaq:CHTP) is scheduled to present at the Sidoti & Company 2010 Semiannual Micro-Cap Conference on June 25, 2010 at the Grand Hyatt Hotel in New York City.
Joseph Oliveto, Chelsea's Vice President of Operations, will provide a brief overview of the company's product pipeline, clinical development status and upcoming milestones. The presentation will not be webcast; however, the slides presented during the conference will be on Chelsea's website at www.chelseatherapeutics.com
The Sidoti Micro Cap Conference provides portfolio managers, investment advisors, pension fund advisors and analysts, retail brokers and high-net-worth individuals with access to management through the combination of a group presentation and one-on-one meetings. More information on the conference, including registration for investors, is located at www.sidoti.com
About Chelsea Therapeutics
Chelsea Therapeutics is a biopharmaceutical development company that acquires and develops innovative products for the treatment of a variety of human diseases. Chelsea's most advanced drug candidate, Northera™ (droxidopa), is an orally active synthetic precursor of norepinephrine initially being developed for the treatment of neurogenic orthostatic hypotension. In addition to Northera, Chelsea is also developing a portfolio of metabolically inert oral antifolate molecules engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders, including two clinical stage product candidates: CH-1504 and CH-4051. Preclinical and clinical data suggest superior safety and tolerability, as well as increased potency versus methotrexate (MTX).
This press release contains forward-looking statements regarding future events. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include risks and costs of drug development, risk of regulatory approvals, our reliance on our lead drug candidates droxidopa and CH-4051, reliance on collaborations and licenses, intellectual property risks, our need to raise additional operating capital in the future, our history of losses, competition, market acceptance for our products if any are approved for marketing, and reliance on key personnel including specifically Dr. Pedder.
CONTACT: Chelsea Therapeutics Investor/Media Relations Kathryn McNeil 718-788-2856